Table I.

Patient characteristics.

Patient no.	Gender	Age (years)	Smoking status	No. of brain metastases	Neurological symptoms	Extracranial lesions	EGFR mutation status	Previous treatment	Initial response to Irresaa
1	Female	68	Non-smoker	Multiple	Absent	Lung, bone	Wild-type	-	-
2	Male	54	Smoker	One	Absent	Lung	Wild-type	Erlotinib	-
3	Male	61	Smoker	Multiple	Polyopia	Lung, bone	Wild-type	-	-
4	Male	73	Non-smoker	Two	Absent	Lung, pleural effusion	Wild-type	S, GP, I,	PD
5	Female	37	Non-smoker	Multiple	Absent	Lung, bone	Wild-type	-	-
6	Female	67	Non-smoker	Multiple	Facial nerve paralysis	Lung, bone	Wild-type	-	-
7	Male	70	Non-smoker	Multiple	Absent	Bone	Wild-type	S, I, DP	NA
8	Male	49	Smoker One	Absent	Lung, bone,	pleural effusion	Wild-type	NP, GP, DP, I	PD
9	Female	72	Non-smoker	Multiple	Dizziness	Lung	Wild-type	DP, I	PD

^aGefitinib. EGFR, epidermal growth factor receptor; S, surgery; GP, gemcitabine plus cisplatin; I, irressa; DP, docetaxol plus cisplatin; NP, navelbine plus cisplatin PD, progressive disease; NA, not applicable.